Business Wire

AGCO Agriculture Foundation to Donate BRL 240,000 to Amigos do Bem institution

3.8.2023 17:02:00 EEST | Business Wire | Press release

Share

The AGCO Agriculture Foundation (the “Foundation”), a private foundation with the vision to prevent and relieve hunger through sustainable agriculture development, will donate BRL 240,000 ($50,000) to Amigos do Bem. The resources will support the “Cashew Project: Transformation Seedlings”, which aims to develop small cashew farmers in the northeast of Brazil, generating work and income and positively impacting extremely vulnerable families.

The donation from the Foundation will be used to purchase and distribute 30,000 fruit tree seedlings, fertilizers and farming kits, as well as provide training, technical support and continuous monitoring of small farmers in the northeast of Brazil. The initiative will support 100 families, reaching more than 500 people directly and indirectly, in addition to supporting the neutralization of 500 tons of CO2 per year with the planting of cashew trees.

“The cashew seedling initiative directly and positively impacts small producers and the environment. Most importantly, it builds a pathway into a guaranteed market for their crops," said Roger Batkin, Chair of the Foundation. “This type of social impact initiative is strongly aligned with the Foundation’s approach for impactful programs that support food security and sustainable agricultural development in rural communities.”

The cashew seedlings to be distributed to farmers will be planted on their own land, with a guaranteed purchase of products at market value, encouraging the role of Brazilian nut suppliers and generating direct and indirect income opportunities.

“By supporting the initiative, we will contribute to transforming the lives of small farmers and their families in the northeastern hinterland, strengthening local agricultural development in a sustainable way and promoting the autonomy and empowerment of these communities,” emphasizes Rodrigo Junqueira, Vice President Massey Ferguson and General Manager South America.

Created in 1993, the nonprofit institution Amigos do Bem promotes continuous education, job and income generation projects and access to water, housing, and health. The social project regularly aids 150,000 people throughout the northeast region of Brazil, with a focus on eradicating extreme poverty. "The Cashew Project started in 2018, with the distribution of surplus seedlings from our own plantations so that small-scale producers could find a source of income and subsistence. It ended up revolutionizing the cashew nut chain in the region," comments André de Luca, Executive Director at Amigos do Bem.

For the next five years, Amigos do Bem project goal is to neutralize 2,300 tons of carbon by planting 150,000 cashew trees, in addition to reaching around 420 farmers, generating income for their families.

About AGCO

AGCO (NYSE:AGCO) is a global leader in the design, manufacture and distribution of agricultural machinery and precision ag technology. AGCO delivers customer value through its differentiated brand portfolio including core brands like Fendt®, GSI®, Massey Ferguson®, Precision Planting® and Valtra®. Powered by Fuse® smart farming solutions, AGCO’s full line of equipment and services help farmers sustainably feed our world. Founded in 1990 and headquartered in Duluth, Georgia, USA, AGCO had net sales of approximately $12.7 billion in 2022. For more information, visit www.AGCOcorp.com. For company news, information, and events, please follow us on Twitter: @AGCOCorp. For financial news on Twitter, please follow the hashtag #AGCOIR.

About AGCO Agriculture Foundation

Founded by AGCO Corporation (NYSE: AGCO) in 2018, the AGCO Agriculture Foundation is a private foundation with the vision to prevent and relieve hunger. The Foundation promotes impact programs that support food security, sustainable agricultural development and build the necessary agricultural infrastructure in marginalized farming communities. The Foundation is domiciled in Vaduz, Liechtenstein and its operations are managed from Duluth, Georgia, USA. For more information, visit https://www.agcofoundation.org/.

About the NGO Amigos do Bem

For 30 years, the Amigos do Bem institution has been working to transform lives in the northeastern hinterland, the poorest and most isolated region in Brazil. Every month, 150,000 people, who live in 300 villages in extreme poverty, are assisted with ongoing projects in education, work and income, water, housing, and health. We promote social inclusion and local development, meeting 12 of the 17 UN Sustainable Development Goals. We created a Sustainable Social Development Model and several initiatives with a positive impact with the participation of almost 11,000 volunteers. For more information, visit https://www.amigosdobem.org/

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Aryn Drawdy, Corporate Communications Director
Aryn.Drawdy@agcocorp.com

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

2PointZero Group Signals Global Scale With Revenue Surge to AED 21.9 Billion and Net Profit of AED 7.7 Billion in H1 202631.7.2026 14:42:00 EEST | Press release

2PointZero Group (ADX: 2POINTZERO), a leading Abu Dhabi-based investment holding firm, announced its financial results for the first half of 2026, reporting revenue of AED 21.9 billion and delivering a Group Net Profit of AED 7.7 billion. This robust performance is reflected in the Group’s adjusted EBITDA, which reached AED 5.0 billion after excluding fair value changes and one-offs. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260731538982/en/ Samia Bouazza, CEO of 2PointZero (Photo: AETOSWire) Net profit from the Group’s businesses increased by 2,301% year-on-year (YoY), driven by the consolidation of Tendam and the mega-merger to form 2PointZero Group, and growth was also supported by new investments in African financial services, entry into the European packaging markets, and steady operational progress across all verticals, bringing the total reported net profit to AED 7.7 billion. Through continued operational integr

Datroway ® Approved in the EU as Only TROP2 Directed Medicine with Overall Survival Benefit for the First-Line Treatment of Patients with Metastatic TNBC Who Are Not Candidates for Immunotherapy31.7.2026 09:30:00 EEST | Press release

Datroway® (datopotamab deruxtecan) has been approved in the European Union (EU) as monotherapy for the first-line treatment of adult patients with unresectable or metastatic triple negative breast cancer (TNBC) who are not candidates for PD-1/PD-L1 inhibitor therapy. Datroway is a specifically engineered TROP2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The approval by the European Commission follows the positive opinionof the Committee for Medicinal Products for Human Use of the European Medicines Agency and is based on results from the TROPION-Breast02phase 3 trial, which were presented at the 2025 European Society for Medical Oncology Congress and subsequently published in Annals of Oncology. In TROPION-Breast02, which included patients with metastatic TNBC who experienced early relapse following prior treatment, Datroway demonstrated a statis

Polpharma Biologics Announces FDA and EMA Acceptance for Review of PB016 Vedolizumab Biosimilar Candidate31.7.2026 09:30:00 EEST | Press release

Polpharma Biologics International AG today announces that the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) have accepted for review the Biologics License Application (BLA) and Marketing Authorisation Application (MAA), respectively, for PB016, a proposed vedolizumab biosimilar candidate to Takeda’s reference product Entyvio®* (vedolizumab) lyophilized vial for intravenous (IV) administration for the treatment of adults with moderately to severely active ulcerative colitis and Crohn's disease. The BLA and MAA acceptances represent significant milestones in Polpharma Biologics' development program and underscore the company's commitment to advancing high-quality biosimilars and expanding global access to affordable biologic medicines. "FDA and EMA acceptances for review of our IV vedolizumab biosimilar candidate mark a major achievement for Polpharma Biologics and validate our deep scientific expertise in biosimilar development and manufacturing," said

Half-Year Report on SES’s Liquidity Contract31.7.2026 08:30:00 EEST | Press release

Pursuant to the liquidity contract entered into by SES with BNP Paribas as of 7 April 2026, please see the below update on the progress of the liquidity services. When the liquidity services were implemented as of 7 April 2026, the following assets were in the liquidity account: € 2,500,000 As of 30 June 2026, the following assets appeared on the liquidity account: 228,186 shares; € 816,880. Over the period from 7 April 2026 to 30 June 2026, the following transactions were executed: 1,082 buy transactions; 1,308 sales transactions. Over this same period, the volumes traded represented: 1,093,335 shares and € 8,485,986 on the buy side; 873,399 shares and € 6,860,843 on the sell side. Follow us on: LinkedIn | Facebook | YouTube | X | Instagram Read our Blogs > Visit the Media Gallery > About SES At SES, we believe that space has the power to make a difference. That’s why we design space solutions that help governments protect, businesses grow, and people stay connected—no matter where th

SES: Disclosure of Share Buyback Transactions31.7.2026 08:30:00 EEST | Press release

In the time period from June 2, 2026 until and including June 23, 2026, a number of 213,167 shares were bought back within the framework of the share buyback of SES to meet obligations under SES’s Equity Based Compensation Plan (EBCP). Shares were bought back as follows: Day of purchase Aggregated volume in shares Daily weighted average acquisition price of shares (EUR) Market June 2, 2026 27,097 8.8727 DXE June 2, 2026 72,903 8.8556 ENX June 5, 2026 16,624 8.3723 DXE June 5, 2026 31,510 8.4266 ENX June 15, 2026 26,451 7.8423 XPAR June 17, 2026 26,812 7.3910 XPAR June 23, 2026 11,770 7.2200 XPAR The transactions in a detailed form are published on SES’s website: https://www.ses.com/investors/shareholder-information/share-buy-backs. Follow us on: Twitter | Facebook | YouTube | LinkedIn | Instagram Read our Blogs > Visit the Media Gallery > About SES At SES, we believe that space has the power to make a difference. That’s why we design space solutions that help governments protect, busin

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye